Share capital (Tables)

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement, Recognized Amount [Abstract]

Schedule of Share Capital

Share capital is composed as follows:

	Issued and outstanding Number of shares December 31,
	2025	2024
Ordinary shares no par value	112,492,667	108,516,819

Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model

	Year ended December 31,
	2025		2024		2023
Stock Option Plans
Expected term (years)	5.50-5.79		5.50-5.73		5.50-6.00
Expected volatility	75%-77%		71%-73%		63%-70%
Risk-free interest rate	4.01%-4.02%		3.88%-4.43%		3.48%-4.79%
Dividend yield	0.00	%	0.00	%	0.00	%
ESPP
Expected term (years)	0.50		0.50		0.50
Expected volatility	56%-89%		73%-90%		56%-122%
Risk-free interest rate	4.16%-4.20%		5.13%-5.23%		4.76%-5.38%
Dividend yield	0.00	%	0.00	%	0.00	%

Schedule of Stock Options to Purchase Ordinary Shares

A summary of the status of the Company’s options to purchase ordinary shares as of December 31, 2025 and changes during the year ended on that date is presented below:

	Year ended December 31, 2025
	Number of options	Weighted average exercise price		Aggregate intrinsic value
Outstanding at beginning of year	11,315,468	$	31.41
Granted	944,888	17.96
Exercised	(429,019)	14.25
Forfeited and cancelled	(1,003,984)	41.99
Outstanding at end of year	10,827,353	$	29.93	$	3,757
Exercisable options	7,023,057	$	34.39	$	3,757

Schedule of RSUs and PSUs

A summary of the status of the Company’s RSUs and PSUs as of December 31, 2025 and changes during the year ended on that date is presented below:

	Year ended December 31, 2025
	Number of RSUs/PSUs	Weighted average grant date fair value price		Aggregate intrinsic value
Unvested at beginning of year	12,066,515	$	27.19
Granted	5,602,761	18.44
Vested	(3,267,379)	24.82
RSUs withheld for tax liabilities	(11,868)	21.79
Forfeited and cancelled	(1,255,375)	31.23
Unvested at end of year (1)	13,134,654	$	23.67	$	169,831

(1)    Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of market and performance conditions which are not probable, as of December 31, 2025, in accordance with ASC 718 as follows:

December 31, 2025
Number of PSUs	Fair value at grant date per PSU		Total fair value at grant date
23,818	$	12.53	$	298
461,652	16.30		7,525
595,755	18.19		10,837
21,653	19.44		421
901,284	48.16		43,406
49,368	76.97		3,800
2,053,530			$	66,287

Schedule of Equity-Based Compensation Expenses Related to Company's Equity-Based Awards

The total equity-based compensation expense related to all of the Company’s equity incentive plans recognized for the years ended December 31, 2025, 2024 and 2023, was comprised as follows:

	Year ended December 31,
	2025		2024		2023
Cost of revenues	$	3,627	$	6,873	$	6,587
Research, development and clinical studies	25,538		32,716		31,827
Sales and marketing	27,121		43,097		35,968
General and administrative	48,546		77,349		41,226
Total share-based compensation expense	$	104,832	$	160,035	$	115,608

Schedule of Stock Option Outstanding

Options outstanding as of December 31, 2025 are as follows:

Exercise price	Number of options outstanding	Weighted average remaining contractual term	Number of options exercisable	Weighted average remaining contractual term
$		(years)		(years)
0.00 - 10.00	278,503	1.12	278,503	1.12
10.01 - 20.00	6,183,256	6.09	2,857,472	3.34
20.01 - 30.00	1,497,482	2.32	1,396,358	1.87
30.01 - 40.00	288,977	4.44	234,531	3.71
40.01 - 60.00	882,345	3.56	882,345	3.56
60.01 - 100.00	1,440,125	5.91	1,117,183	5.62
100.01 - 160.00	247,403	5.24	247,403	5.24
160.01 - 220.00	9,262	5.41	9,262	5.41
	10,827,353	5.14	7,023,057	3.43